A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
|Slideshows|January 6, 2021
Cervical Cancer Awareness: Facts, statistics and more
Author(s)Lindsey Carr, Editor
In honor of Cervical Cancer Awareness month, Contemporary OB/GYN® will publish weekly slideshows with factual information, statistics, and more.
Advertisement
Advertisement
Related to this article
The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.
Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Reactions to FDA's boxed warning removals for menopausal hormone therapy
3
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
4
Top headlines in women's health from October 2026
5